BCPP BIODA
BC Psychosis Program Biobank and Database for Investigating Genetic Polymorphisms of Brain-derived Neurotrophic Factor and Catechol-o-methyl Transferase and Their Associations With Psychosis Disorder
Sponsor study identifier
observational
200
1 country
1
Study Start
July 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to determine if candidate polymorphisms in brain-derived neurotrophic factor (BDNF) and catechol-o-methyl transferase (COMT) are predictive of psychosis disorder severity, symptomology, and resolution in patients at BCPP. A secondary objective will be to form a biorepository of blood and saliva samples from patients at BCPP so that further genetic, proteonomic and pharmacogenomic studies may be done to gain insight into the genetic basis of differences in psychosis disorder presentation and manifestation, and differences in response to antipsychotic drug treatment.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 2014
Date type not reportedThis date has not been verified as actual or estimated.
December 12, 2014
Actual (reported)December 23, 2014
Actual (reported)July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Creation of biorepository of blood samples for future genetic, proteonomic and pharmacogenomic studies.
A biobank of stored samples will be used to determine the genetic variability in psychosis disorder.
One visit during participant's stay at BCPP, an expected average of 6 months
Identification of single-nucleotide polymorphisms (SNPs) in the BDNF and COMT genes
One visit during participant's stay at BCPP, an expected average of 6 months
Medical Chart Review
One visit during participant's stay at BCPP, an expected average of 6 months
Blood or saliva samples will be collected from participants for whole genomic/transcriptomic sequencing
Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The population will include all patients who have been admitted to the British Columbia Psychosis Program (BCPP). BCPP provides intensive inpatient care for individuals who have psychosis-related treatment challenges, including pharmacologic, biophysical, and psychosocial services. Admission criteria to BCPP include the following: 1) Must be 18 years or older; 2) Diagnosis of schizophrenia, schizoaffective disorder, mood disorder with psychosis; 3) History of no response or inadequate response of positive symptoms to at least 2 adequate trials of antipsychotics (one of which is a second generation agent) by health authority tertiary clinical teams; 4) Incomplete recovery of social, vocational, and occupational functioning and 5) If present, substance use disorder, pervasive developmental disorder, developmental disability, personality disorder, aggression, or head injury are not the primary focuses of treatment.
University of British Columbia Hospital - BC Psychosis Program
Vancouver, British Columbia, V6T 2A1, Canada
We will be collecting and retaining whole blood samples and saliva samples for genomic testing.
Alasdair M Barr, Ph.D.
University of British Columbia
First Submitted
December 12, 2014
First Posted
December 23, 2014
Study Start
July 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
July 2018
Estimated (date passed)Virtual Cognitive Behavioural Therapy for Psychosis
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
June 1, 2016
Record last verified: 2016-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: